key: cord-0827788-zqjadbvh
authors: Servellita, V.; Syed, A. M.; Brazer, N.; Saldhi, P.; Garcia-Knight, M.; Sreekumar, B.; Khalid, M. M.; Ciling, A.; Chen, P.-Y.; Kumar, G. R.; Gliwa, A. S.; Nguyen, J.; Sotomayor-Gonzalez, A.; Zhang, Y.; Frias, E.; Prostko, J.; Hackett, J.; Andino, R.; Doudna, J.; Ott, M.; Chiu, C. Y.
title: Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
date: 2022-01-26
journal: nan
DOI: 10.1101/2022.01.25.22269794
sha: dd0cf99e83b65cb1416f9f2f7c4e17598614098e
doc_id: 827788
cord_uid: zqjadbvh

Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity to Delta and Omicron SARS-CoV-2 variants in 239 samples from 125 fully vaccinated individuals. In uninfected, non-boosted individuals, VLP neutralization titers to Delta and Omicron were reduced 2.7-fold and 15.4-fold, respectively, compared to wild-type (WT), while boosted individuals (n=23) had 18-fold increased titers. Delta breakthrough infections (n=39) had 57-fold and 3.1-fold titers whereas Omicron breakthrough infections (n=14) had 5.8-fold and 0.32-fold titers compared to uninfected non-boosted and boosted individuals, respectively. The difference in titers (p=0.049) was related to a higher proportion of moderate to severe infections in the Delta cohort (p=0.014). Correlation of neutralizing and spike quantitative antibody titers was decreased with Delta or Omicron compared to WT. Neutralizing antibodies in Delta and Omicron breakthrough infections increase overall, but the relative magnitude of increase is greater in more clinically severe infection and against the specific infecting variant.

Variants of concern have emerged throughout the COVID-19 pandemic, causing multiple waves of CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint 4 66 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2022. 1A and B). In comparison, live virus neutralization titers to Delta and Omicron were both reduced 3.0-fold (120 94 → 40), with the lower reduction for Omicron accounted for by the higher limit of detection (LOD) for the live 95 virus (NT50 = 40) compared to the VLP neutralization assay (NT50 = 10). Using VLPs, the proportion of 96 individuals with neutralizing antibodies to Omicron above an NT50 cutoff of 40 was ~20%, as compared to 97 ~80% and ~95% for Delta and WT, respectively ( Figure 1C, left) . The corresponding proportions using live 98 viruses were ~5%, ~45%, and ~75% for Omicron, Delta, and WT, respectively ( Figure 1C , right). In boosted 99 individuals, baseline VLP titers to WT were 18-fold higher (4,727 versus 262) than in non-boosted individuals 00 ( Figure 1A , B, D, and E, left), and decreases in titers to Delta and Omicron relative to WT were more modest 01 at 3.3-fold and 7.4-fold, respectively ( Figure 1D and E, left) . The increase in VLP neutralization titers 02 corresponded to >93% of boosted individuals having neutralizing antibodies to all 3 lineages above an NT50 WT decreased by 93% (14-fold, 2,043→146) over >3 months following vaccination, with decreases in titers to 07 Delta and Omicron of 2.9--4.7-fold and 12.2-43.5-fold, respectively, relative to WT ( Figure 1G ). 08 09 10 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint 7 11 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Using VLP assays, we found that Delta breakthrough infections (n=39), 5 of which were boosted, had CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint bottom). Partial neutralization to Omicron was observed mainly due to the increase in baseline titers, as there 37 appeared to be limited cross-variant immunity with 31.1-fold and 46.8-fold decreases in Omicron neutralization 38 relative to WT for the VLP and live assays, respectively (Figure 2A) . The proportion of individuals with 39 neutralizing antibodies to Omicron above an NT50 cutoff of 40 was calculated at ~75% (Figure 2A , top right) 40 and ~43% (Figure 2A, bottom right) for the VLP and live virus assays, respectively. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint 10 reduction in Omicron titers in Delta breakthroughs (Figure 2A and B) , comparable to the reductions observed 61 in uninfected vaccinated individuals ( Figure 1A ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint 11 63 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. nfections.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. Clinical severity is a potential determinant of neutralizing immunity 86 We sought to identify clinical factors that may explain the difference between neutralizing antibody 87 levels between Delta and Omicron breakthrough infections. Univariate analysis revealed that among the factors 88 examined, only clinical severity, hospitalization for COVID-19, and median numbers of days between symptom 89 onset or PCR positivity and sample collection, were significant (Table 1) . Notably, there was a higher 90 proportion of moderate to severe infections in Delta compared to Omicron breakthrough cases (Table 1, is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint moderate levels of spike IgG antibody failed to neutralize Omicron in the live virus assay (Figure 4B, bottom) . 11 Quantitative NT50 titers of 10 3 -10 4 and >10 5 reliably predicted Delta and Omicron neutralization, respectively. Omicron breakthrough cohorts were associated with significantly higher neutralization titers than mild or 25 asymptomatic infections among immunocompetent patients (p=0.022).

A limitation of the current study is the lack of both acute and convalescent samples from patients with 27 Delta or Omicron breakthrough infections. Indeed, we found a significant difference in the median days 28 between symptom onset or PCR positivity and sample collection (Table 1, 17 versus 8.5 days, p=0.008) . 29 However, when we analyzed a more comparable subset of samples collected is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint individuals using a pseudovirus assay, comparable to the 7.4-fold reduction that we observed using a VLP syringe filter. For other culture sizes, the mass of DNA used was 1 µg for 24-well, 4 µg for 6-well, 20 µg for 94 10-cm plate and 60 µg for 15-cm plate. Optimem volumes were 100 µL, 400 µL, 1 mL and 3 mL respectively 95 and PEI was always used at 3:1 mass ratio.

Each heat inactivated serum sample was serially diluted from 1:20 to 1:20480 dilution in complete 97 DMEM media prior to incubation (1hr at 37°C) with 40μL VLPs with total volume of 50μL, then plated onto 98 receiver cells (50000 293T ACE2-TMPRSS2 cells). Next day, supernatant was removed and cells were lysed in 99 20 µL passive lysis buffer (Promega) for 15 minutes at room temperature with gentle rocking. Lysates were 00 transferred to an opaque white 96-well plate and 30 µL of reconstituted luciferase assay buffer was added and 01 mixed with each lysate. Luminescence was measured immediately after mixing using a TECAN plate reader.

Neutralization titer (NT50) was estimated by fitting the interpolating the dilution of serum at which 50% 03 infectivity was observed.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint Vero E6-TMPRSS2-T2A-ACE2 and Vero-81 were cultured with MEM supplemented with 1x 06 penicillin-streptomycin (Gibco), glutamine (Gibco) and 10% Fetal calf serum (Hyclone). The Vero E6-07 TMPRSS2-T2A-ACE2 were also supplemented with 10ug/mL puromycin.

The Omicron and Delta variants were isolated from a patient NP swab. To isolate Delta, 200ul of a 09 nasopharyngeal (NP) sample that was previously sequence identified as Delta, was diluted 1:3 in PBS 10 supplemented with 0.75% bovine serum albumin (BSA-PBS) and added to confluent Vero-81 cells in a T25 11 flask, allowed to adsorb for 1 hour, then additional media was added and the flask was incubated at 37˚C with 12 5% CO2 with daily monitoring for CPE. When 50% CPE was detected, the contents were collected, clarified by 13 centrifugation and stored at -80C as passage 0 stock. Passaged stock of Delta was made by inoculation of Vero-14 81 confluent T150 flasks with 1:10 diluted p0 stock, monitored and harvested at approximately 50% CPE.

Omicron viral stock was similarly produced from a sequence confirmed NP sample using Vero E6-TMPRSS2-16 T2A-ACE2 in a T25 and harvested at 90% CPE with no subsequent passaging. Both viral stocks were 17 sequenced to confirm lineage and TCID50 was determined by titration. Individual wells were scored for CPE as having a binary outcome of 'infection" or 'no infection' and the IC50 29 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint 26 was calculated using the Spearman-Karber method. All steps were done in a Biosafety Level 3 lab using 30 approved protocols.

Statistical analyses and data visualization were performed using R (version 4.0.3) and Python (version 33 3.7.10). Fisher's exact test was used to evaluate associations of demographic and clinical variables with variant-34 specific breakthrough infections. Fold decreases in neutralizing activity were measured by comparing median 35 neutralizing antibody titers. Significance testing was performed using the Wilcoxon signed-rank test and Mann-36 Whitney U test for paired and unpaired samples, respectively. Correlation coefficients were calculated using 37 Spearman's rank analysis. Plots were generated using ggplot2 (version 3.3.5) in R and seaborn package (version 38 0.11.0) in Python. All statistical tests were conducted as two-sided at the 0.05 significance level. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint

Omicron escapes the majority of existing SARS-CoV-2 neutralizing 50 antibodies

Neutralizing Antibody and Soluble ACE2 Inhibition of a 53

Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

SARS-CoV-2 B.1.1.529 (Omicron) Variant -United States

Variants (California Department of Public Health)

Outcomes of laboratory-confirmed SARS-CoV-2 63 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province

Possible future waves of SARS-CoV-2 infection generated by 67 variants of concern with a range of characteristics

Omicron, the great escape artist

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted January 26, 2022. ; https://doi.org/10.1101/2022.01.25.22269794 doi: medRxiv preprint